Terkaa Atim

Dr. Terkaa Atim

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in African Journal of Paediatric Surgery
Verified
Journal Article
Open access
PDF file
OAOseremen Inokhoife Aisuodionoe-Shadrach
Oseremen Inokhoife Aisuodionoe-Shadrach
TATerkaa Atim
Terkaa Atim
BEBolarinwa Sefiu Eniola
Bolarinwa Sefiu Eniola
AOAlexander Akogwu Ohemu
Alexander Akogwu Ohemu
Background: To determine the outcome of hypospadias repair in children. Patients and Methods: This was a retrospective study of all patients with hypospadias managed at the University of Abuja Teaching Hospital, Abuja, Nigeria from January 2009 to December 2013. Results: Twenty-four cases of hypospadias had corrective surgery during the 5-year period under review. Seventy-five percent of the patients (n = 18) were seen after the 1 st year of life. There were two peaks of ages at corrective repair; 45.8% between age 1 and 3 years and 29.1% between age 5 and 10 years. The average age at time of surgery was 44.9 months. Distal hypospadias were more common (58.4%), followed by glanular (20.8%) and proximal (20.8%) hypospadias. Associated anomalies included chordee, maldescended testicles and inguinal hernia in 20.8%, 4.1% and 8.3% cases, respectively. Operative techniques were single-stage procedures in 79.1% of patients consisting of simple circumcision in two cases (10.5%), Mathieu's peri-meatal based flap in four cases (21%), meatal advancement and glanuloplasty incorporated in three cases (16%) and Snodgrass tubularised incised urethral plate tubularised incised plate in 10 cases (52.5%). The remaining 20.9% (n = 5) had multi-staged procedures. The most common post-operative complications were urethrocutenous fistula in nine patients (33.3%) and metal stenosis in 3 patients (12.5%). Conclusions: Our results show that hypospadia repair is froth with attendant high complications in our setting.

1 June 2016 in African Journal of Urology
Verified
Journal Article
Open access
TATerkaa Atim
Terkaa Atim
AMAbdulrahman Mukhtar
Abdulrahman Mukhtar
Adrenal cysts are rare cystic masses that arise from the adrenal gland. They are usually non-functional, asymptomatic and less than 10 cm in diameter when discovered incidentally. However, giant adrenal cysts are cysts of the adrenal gland which are larger than 10 cm in diameter. They pose a diagnostic conundrum to the surgeon as localization of the origin of the cyst is very difficult. Indications for surgical intervention include a size exceeding 10 cm in diameter, the presence of symptoms, endocrine abnormalities, intracystic bleeding and suspicion of malignancy. The current treatment of choice is adrenalectomy, either open or laparoscopic. Ultrasound-guided percutaneous drainage is an alternative, especially when there is no doubt regarding the diagnosis. Following, we report on one of the rare cases of a giant adrenal cyst.

23 July 2019 in International Journal of TROPICAL DISEASE & Health
Verified
Journal Article
Open access
PDF file
SAS. Abu
S. Abu
TATerkaa Atim
Terkaa Atim
NRN. R. Ripiye
N. R. Ripiye
Introduction: Erectile dysfunction (ED) is the most common male sexual dysfunction all over the World. It is underestimated in developing countries including Nigeria because it is assumed not to be a life threatening condition which is associated with stigmatization and poor health seeking behavior. The Prevalence rate of ED among specific age groups has not been reported in most available local studies. This study was aimed at determining the prevalence rates of ED and the severity of ED among different age groups and patients’ awareness of its treatment. Methods: The study was a descriptive cross-sectional hospital based survey among men aged 18 years and above seen in the outpatient clinics of University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria. Self reported erectile dysfunction was obtained using proforma. The prevalence and severity of ED was obtained using International Index of Erectile Function-5 Questionnaire (IIEF-5). Results: A total of 378 subjects were recruited for this study with age range of 18-76 years. The prevalence of ED in this study using IIEF-5 was 66.4%. The prevalence of ED was noted to increase with increasing age as ED was more prevalent (59%) among men aged 60-79 year. ED was least common among the young subjects (15.7%) and the most severe ED found among the elderly There was a positive correlation between age and ED (rho =0.306). There was statistically significance association between ED and co-morbidities with hypertension accounting for 22.5% and diabetes 16.7%. The percentage of subjects aware of treatment for ED was 39.4% and 20.4% of the subjects had sought help from doctors. Only about a quarter (26.5%) of the subjects had their sexual challenges discussed with the doctor. Conclusion: ED is a common medical and social problem in our environment though still shrouded in secrecy. ED is more prevalent and severe among age 60-79 years. Awareness of treatment seeking behavior and the ability of the attending physicians to discuss with men about their sexual health remains quite poor in our environment.

22 September 2025 in Onco
Verified
Journal Article
Open access
PDF file
MEMichael Enwere
Michael Enwere
EIEdward Irobi
Edward Irobi
VCVictoria Chime
Victoria Chime
AEAda Ezeogu
Ada Ezeogu
AOAdamu Onu
Adamu Onu
LJLaurens Holmes, Jr
Laurens Holmes, Jr
Background: Despite advances in gene-targeted and immunotherapies, many aggressive cancers—including glioblastoma and triple-negative breast cancer—remain refractory to treatment. Mounting evidence implicates metabolic reprogramming, especially dysregulation of glucose and glutamine metabolism, as a core hallmark of tumor progression. Natural compounds with metabolic-modulatory effects have emerged as promising adjuncts in oncology. Research Question and Objectives: This review investigates the following question: How can metabolic-targeted therapies—particularly those modulating the Warburg effect and glutamine metabolism—improve cancer treatment outcomes, and what role do natural compounds play in this strategy? The objectives were to (1) evaluate the therapeutic potential of metabolic interventions targeting glucose and glutamine metabolism, (2) assess natural compounds with metabolic regulatory activity, (3) examine integration of metabolic-targeted therapies with conventional treatments, and (4) identify metabolic vulnerabilities in resistant malignancies. Methods: A qualitative systematic review (QualSR) was conducted following PRISMA guidelines. A total of 87 peer-reviewed studies published between 2000 and 2024 were included. Inclusion criteria required clearly defined mechanistic or clinical endpoints and, for clinical trials, sample sizes ≥ 30. Data extraction focused on tumor response, survival, metabolic modulation, and safety profiles. Results: Curcumin significantly reduced serum TNF-α and IL-6 (both p = 0.001) and improved antioxidant capacity (p = 0.001). EGCG downregulated ERα (p = 0.002) and upregulated tumor suppressors p53 and p21 (p = 0.001, p = 0.02). High-dose intravenous vitamin C combined with chemoradiotherapy yielded a 44.4% pathologic complete response rate in rectal cancer. Berberine suppressed Akt/mTOR signaling and glutamine transporter SLC1A5 across tumor types (q < 10−10). However, poor bioavailability (e.g., EGCG t½ = 3.4 ± 0.3 h) and systemic toxicity limit their standalone clinical application. Conclusions: Metabolic-targeted therapies—particularly natural compounds acting on glucose and glutamine pathways—offer a viable adjunct to standard cancer therapies. Clinical translation will require biomarker-driven patient stratification, improved delivery systems, and combination trials to optimize the therapeutic impact in treatment-resistant cancers.

1 January 2022 in Pan African Medical Journal
Verified
Journal Article
Open access
TATerkaa Atim
Terkaa Atim
JAJoshua Oluwafemi Aiyekomogbon
Joshua Oluwafemi Aiyekomogbon
Paragangliomas are extremely rare neuroendocrine tumors with an incidence of 0.3 cases per million in children. They arise from several sites in the body including the orbit, ear, nose, larynx, carotid area, mediastinum, duodenum, and the genitourinary tract. Germline mutations have been identified in paragangliomas involving the proto-oncogene RET, tumor suppressor genes VHL, and NF1 The commonest clinical presentation is hypertension but incidentally detected forms have been reported during imaging and on a few occasions the diagnosis was missed. The authors report on a case of a 12-year-old male with a history of fever, left flank pain, vomiting, and headaches, finally diagnosed by pathological examination of a resected retroperitoneal mass invading the proximal left ureter. Immunohistochemistry was positive for neuron-specific enolase, NSE (chief cells), and S-100 protein (sustentacular cells) all consistent with paragangliomas. The challenges faced by the team in the preoperative evaluation and surgical treatment are reported.

16 January 2025 in International Journal of Clinical Urology
Verified
Journal Article
Open access
PDF file
OKObiatuegwu Kenenna
Obiatuegwu Kenenna
TATerkaa Atim
Terkaa Atim
MFMagnus Felix
Magnus Felix
OCOtabor Christopher
Otabor Christopher
AOAmu Okwudili
Amu Okwudili
ASAbu Sadiq
Abu Sadiq
Introduction : QuadMix is considered to be one of the most powerful class of anti-erectile dysfunction agents and superior to all forms of intracavernosal injections especially in men with permanent/severe erectile dysfunction (ED) that has defiled oral therapy. QuadMix consists of papaverine HCl, phentolamine mesylate, prostaglandin E1 and atropine sulfate designed to act synergistically with satisfactory endpoint. We report our preliminary experience with QuadMIX in the management of permanent/severe ED. Methodology : This is a prospective study which was carried out between July 2020 to June 2022. Two questionnaires (a proforma and IIEF-5) were administered to all patients presenting with ED to objectively assess the etiology, risk factors and severity of ED without bias. Only patients who met the inclusion criteria were recruited for the study and informed consent was obtained. Individual test dose was calculated and the patients were subsequently trained on self-injection using an autoinjector. Two capsules of phenylephrine were also given to the patients to keep with them with appropriate instructions. Data obtained were analyzed using Statistical Package for Social Sciences version 20.0. P value of less than 0.005 was considered statistically significant. Results : Sixty patients were enrolled for the study. All patient had either permanent ED or severe ED. Thirty percent had radical prostatectomy surgery. Ten percent had trauma with pelvic bone involvement while 31.66%, 3.34% and 25% had comorbid conditions (diabetes mellitus and hypertension), prolonged priapism and no obvious organic etiology respectively. Forty percent of the patients failed to achieve satisfactory erection on oral medication while 60% had no erection despite taking phosphodiesterase type 5 inhibitors (PDE5i). All patients had tumescence for satisfactory sexual intercourse within 10 mins following administration of QuadMix. Fifty eight patients (96.67%) had spontaneous detumescence after ejaculation. Only 2 patients (3.34%) had priapism. One was reversed with ejaculation, use of ice pack around the perineum and caps phenylephrine while the second patient had intracavernosal aspiration to achieve detumescence. Conclusion : QuadMix is an effective and safe agent in the treatment of permanent and severe ED in patients with comorbid condition. It also improves quality of life (QoL) and sexual performance in patient who has had permanent ED following radical prostatectomy.